Physician profile
Renee A Mirovsky
NPI 1740461185
$2,899.75
in general payments reported to CMS, 2019-2025
25 companies · $838 in 2025
The $838 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $364 · 2022: $537 · 2023: $630 · 2024: $531 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,998.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $578.70 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $394.02 | 2021-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.45 | 2021-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $350.52 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $220.63 | 2021-2025 | Mounjaro, Kisunla, Jardiance |
| Abbvie INC. | $211.85 | 2021-2025 | |
| Glaxosmithkline, LLC. | $137.72 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $101.79 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $95.75 | 2022 | |
| Exact Sciences Corporation | $69.75 | 2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $53.26 | 2021-2023 | Veozah |
| Xeris Pharmaceuticals, INC. | $47.79 | 2021 | |
| Abbott Laboratories | $46.02 | 2023 | Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.18 | 2023 | |
| Madrigal Pharmaceuticals | $24.34 | 2025 | Rezdiffra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21.58 | 2022 | |
| Amarin Pharma, INC. | $18.93 | 2021 | |
| Braeburn INC. | $17.56 | 2025 | Brixadi |
| Novartis Pharmaceuticals Corporation | $17.22 | 2022 | |
| Horizon Therapeutics Plc | $14.93 | 2023 | Krystexxa |
| Hologic Sales and Service, LLC | $14.40 | 2022 | |
| Evoke Pharma, INC. | $13.95 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.45 | 2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $13.27 | 2022 | |
| Alfasigma USA, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Mirovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.